PREMIER: Lifestyle Interventions for Blood Pressure Control (PREMIER) - Catalog
-
Name
PREMIER: Lifestyle Interventions for Blood Pressure Control (PREMIER)
-
Accession Number
HLB00540609a
-
Acronym
PREMIER
-
Related studies
-
BSI Study IDs
PRE
-
Is public use dataset
False
-
Keywords
-
Ingestion StatusReleased
-
Has Study Datasets
True
-
Has Specimens
True
-
Specimen ID TypeCoded
-
Study Website
-
The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.
False
-
Clinical Trial URLs
-
Study typeClinical Trial
-
Collection TypeOpen BioLINCC Study
-
Cohort typeAdult
-
Interventions
Behavioral: diet, sodium-restrictedBehavioral: diet, fat-restrictedBehavioral: exerciseBehavioral: diet, reducingBehavioral: alcohol drinking
-
Study Open Date (Data)
2009-10-01
-
Study Open Date (Specimens)
2010-10-29
-
Date materials available
2009-05-20
-
Last updated
2006-05-08
-
Study period
1998-2004
-
Study Contacts
-
NHLBI Division
DCVS
-
ClassificationHeart
-
HIV study classificationnon-HIV
-
COVID study classificationnon-COVID
-
Pre-Website # of Specimens Shipped
2211
-
# of Returned Specimens
0
-
Primary Publication URLs
-
Commercial use data restrictionsNo
-
Data restrictions based on area of researchNo
-
Commercial use specimen restrictionsNo
-
Non-genetic use specimen restrictions based on area of useYes
-
Genetic use of specimens allowed?Yes
-
Genetic use area of research restrictionsYes
-
Specific Consent Restrictions
Restrictions are related to genetic/non-genetic biospecimen use by research topic.
-
ConditionsHeart Diseases
Hypertension
-
Objectives
To determine the effect on blood pressure (BP) of 2 multicomponent, behavioral interventions.
-
Background
Weight loss, sodium reduction, increased physical activity, and limited alcohol intake are established recommendations that reduce BP. The Dietary Approaches to Stop Hypertension (DASH) diet also lowers BP. To date, no trial has evaluated the effects of simultaneously implementing these lifestyle recommendations.
-
Participants
Randomized trial with enrollment at 4 clinical centers (January 2000-June 2001) among 810 adults (mean [SD] age, 50 [8.9] years; 62% women; 34% African American) with above-optimal BP, including stage 1 hypertension (120-159 mm Hg systolic and 80-95 mm Hg diastolic), and who were not taking antihypertensive medications.
-
Design
Randomized controlled clinical trial that tested two behavioral interventions compared with an advice-only group over a period of 18 months. The two interventions promoted established recommendations that reduce BP. One intervention in addition promoted the DASH diet, which is rich in fruits, vegetables, and low-fat dairy products, and low in saturated fat, total fat, and cholesterol.
-
Conclusions
Individuals with above-optimal BP, including stage 1 hypertension, can make and largely sustain multiple lifestyle changes. These lifestyle changes lower BP, improve BP control, and may reduce cardiovascular disease risk. (JAMA 2003;289:2083-2093; Ann Intern Med 2006;144:485-495).
-
Disease classification
-
Publications
-
Mat typesBuffy Coat
Plasma
Serum
Urine
-
Network
The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.
-
Subjects
Premier A: 273
Premier B: 268
Premier C: 269
Last Modified: Feb. 7, 2024, 1:43 p.m. -
Age
Premier A
Premier B
Premier C
Total Subjects
=< 30
2
6
3
11
31-35
12
8
11
31
36-40
22
21
26
69
41-45
53
37
44
134
46-50
74
69
49
192
51-55
50
57
63
170
56-60
25
40
41
106
61-65
19
20
20
59
66-70
12
7
5
24
>= 71
4
3
7
14
Last Modified: Feb. 7, 2024, 1:46 p.m. -
Sex
Premier A
Premier B
Premier C
Total Subjects
Male
101
94
115
310
Female
172
174
154
500
Last Modified: Feb. 7, 2024, 1:46 p.m. -
Race
Premier A
Premier B
Premier C
Total Subjects
non-Black
173
168
190
531
Black
100
100
79
279
Last Modified: Feb. 7, 2024, 1:46 p.m.
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3.0 of the BioLINCC Handbook describes the components of the review process.
-
Material Types
Serum, Plasma, Buffy Coat, Urine
Last Modified: Feb. 7, 2024, 1:43 p.m. -
General Freeze/Thaw Status
As of 02/07/2024, about 2/3 of serum specimens , 1/2 of plasma specimens, and 3/4 of urine specimens have undergone at least 1 freeze-thaw cycle. Buffy coat specimens are unthawed.
Last Modified: Feb. 7, 2024, 1:43 p.m. -
Visits (Vials)
02/07/2024
Serum
Plasma
Buffy Coat
Urine
Total Vials
Baseline
3,845
2,553
791
6,630
13,819
6 Month
3,581
2,423
.
5,954
11,958
18 Month
4,175
2,779
.
7,037
13,991
Unknown
3
.
.
.
3
Last Modified: Feb. 7, 2024, 1:48 p.m. -
Visits (Subjects)
02/07/2024
Serum
Total number of subjects
Average volume (mL) per subject
Baseline
806
4.39
6 Month
741
4.37
18 Month
751
4.24
Unknown
3
1.18
Plasma
Total number of subjects
Average volume (mL) per subject
Baseline
804
2.84
6 Month
741
2.92
18 Month
750
2.90
Buffy Coat
Total number of subjects
Average volume (mL) per subject
Baseline
791
1.01
Urine
Total number of subjects
Average volume (mL) per subject
Baseline
802
15.12
6 Month
640
14.85
18 Month
688
18.98
Last Modified: Feb. 7, 2024, 1:48 p.m.